News

Luye Pharma Announces First Subject Enrolled in U.S. PK Bridging Clinical Trial of Its VMAT2 Inhibitor/Sigma-1R Agonist LY03015

Luye Pharma Announces U.S. Launch of ERZOFRI^® (paliperidone palmitate) Extended-Release Injectable Suspension for the Treatment of Schizophrenia and Schizoaffective Disorder

January 14, 2025

Luye Pharma’s Dual TAAR1/5-HT2CR Agonist LY03020 Approved for Clinical Trials in the U.S.

Luye Pharma’s Manufacturing Facility for Paliperidone Palmitate Extended-release Injectable Suspension (LY03010) Passes FDA’s PAI with No FDA-483 Issued

October 09, 2023

NDA for Luye Pharma’s Paliperidone Palmitate Extended-release Injectable Suspension Submitted in the U.S.